James C. Borel, a director at Neogen Corp, has reported significant stock transactions that reflect his ongoing commitment to the company. This update is notable as it showcases Borel's investment in Neogen, a player in the life sciences sector, particularly in in vitro and in vivo diagnostic substances.
According to the recent SEC filing, Borel engaged in two key transactions on October 1, 2026. He acquired 9,804 restricted stock units at a price of $12.24 per share. Following this transaction, he now owns a total of 106,151 shares. Additionally, Borel reported acquiring 20,558 shares of common stock through options, also at a price of $12.24 per share. These options are set to expire on October 1, 2036.
Neogen Corp, which operates under the ticker symbol NEOG, is known for its focus on diagnostic products and services for the food and animal industries. The company is incorporated in Michigan and has been active in the life sciences field, particularly in the development of diagnostic substances.
The filing reveals that Borel's transactions are part of a broader pattern of ownership changes, as he has been actively reporting stock transactions over the past few years. In fact, this is not the first time Borel has reported stock transactions; he has filed similar reports multiple times since 2021.
These transactions may have implications for Neogen Corp's stakeholders, including investors and employees, as they indicate Borel's confidence in the company's future. The life sciences sector is highly competitive, and Borel's actions could signal to other industry players the potential for growth within Neogen.
As for what comes next, the filing does not specify any further actions or upcoming events related to these transactions. Stakeholders will be watching closely to see how Neogen continues to navigate its market position in the coming months.